BridgeMD
Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke
EU CTIS ID: 2025-521260-35-00
What this study is testing
To test whether early rhythm-control therapy in addition to usual care reduces the rate of adverse cardiovascular outcome in patients with acute ischemic stroke and atrial fibrillation (AF) compared to usual care alone.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Acute ischemic stroke confirmed with standard of care brain imaging or clinical diagnosis
- Randomisation within 4 weeks of stroke (but as early as possible)
- AF first detected ≤1 year before randomisation (including paroxysmal AF)
- At least one ECG within recent 12 months that documents AF
- Age >45 years
- Written informed consent
You likely can't join if
- End-stage cancer or life-expectancy <12 months
- Prior AF ablation or surgical therapy for AF
- Patients not suitable for early rhythm control of AF
- History of AF first diagnosed >12 months prior to randomization
The study team makes the final eligibility decision.
Where it's taking place
- Switzerland
- United Kingdom
- Canada
- Australia
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Switzerland; United Kingdom; Canada; Australia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.